{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:21:11Z","timestamp":1787462471556,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T00:00:00Z","timestamp":1225843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T00:00:00Z","timestamp":1225843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Patients with rheumatoid arthritis (RA) have an increased frequency of osteoporosis, mainly because of increased bone resorption. Reduction of disease activity is suggested to reduce bone remodelling. It might also be possible that prednisolone treatment could cause this effect because prednisolone has been shown to arrest the development of joint destruction in early RA. Therefore, we examined the effects of low-dose prednisolone on serum concentrations of bone remodelling markers and insulin-like growth factor-1 (IGF-1) in RA patients in relation to bone mineral density.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>One hundred and fifty patients, 67% women, with early RA, mean disease duration of six months (95% confidence interval (CI) = three to eight months), who had participated in the BARFOT (Better Anti-Rheumatic FarmacOTherapy) low-dose prednisolone study were included. They had been randomised to either the P-group, who were treated with 7.5 mg prednisolone daily (n = 70, mean age = 51 years, 95% CI 48 to 54 years), or the NoP-group, who received no prednisolone (n = 80, mean age 58 years, 95% CI 56 to 61 years), when they started their first disease-modifying anti-rheumatic drug (DMARD). Serum samples were analysed at baseline, 3 and 12 months for procollagen type I N-terminal propeptide (P1NP), a marker of bone formation, and the C-telopeptide crosslaps of type I collagen (CTX-1) and C-terminal telopeptide of type I collagen (1CTP), markers of bone degradation. IGF-1 was analysed at baseline and after 12 months. Bone mineral density at the lumbar spine and femoral neck was assessed by dual-energy X-ray absorptiometry at baseline and after 24 months.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Levels of P1NP decreased rapidly in the P-group (p &lt; 0.001). Levels of CTX-1 and 1CTP decreased in both treatment groups, but significantly more in the P-group (differences between groups p &lt; 0.019 and p &lt; 0.001, respectively). IGF-1 increased in the P-group (p &lt; 0.001) but remained stable in the NoP-group. Bone mineral density decreased in the spine in both groups, significantly more in postmenopausal women from the P-group. Femur bone mineral density only decreased in the NoP-group.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Low-dose prednisolone in early RA counteracts the negative impact of rheumatoid inflammation on bone tissue in the hip, a juxta-articular localisation. Thus bone mineral density was preserved in the femur in the P-group and 1CTP decreased rapidly. However, the systemic inflammatory consequences on bone could not be prevented in the lumbar spine, especially not in postmenopausal women, probably because of the combined effect of suppression of bone synthesis by prednisolone and the postmenopausal status.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar2542","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T20:30:44Z","timestamp":1225917044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study"],"prefix":"10.1186","volume":"10","author":[{"given":"Inga-Lill","family":"Engvall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Tengstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Brismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingi\u00e4ld","family":"Hafstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BARFOT study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,5]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/rheumatology\/35.4.309","volume":"35","author":"AA Deodhar","year":"1996","unstructured":"Deodhar AA, Woolf AD: Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996, 35: 309-322. 10.1093\/rheumatology\/35.4.309.","journal-title":"Br J Rheumatol"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/art.1780271205","volume":"27","author":"JR Hooyman","year":"1984","unstructured":"Hooyman JR, Melton LJ, Nelson AM, O'Fallon WM, Riggs BL: Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984, 27: 1353-1361. 10.1002\/art.1780271205.","journal-title":"Arthritis Rheum"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/bmj.306.6877.558","volume":"306","author":"TD Spector","year":"1993","unstructured":"Spector TD, Hall GM, McCloskey EV, Kanis JA: Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993, 306: 558-","journal-title":"BMJ"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.amjmed.2005.12.020","volume":"119","author":"SL Bonnick","year":"2006","unstructured":"Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006, 119: S25-31. 10.1016\/j.amjmed.2005.12.020.","journal-title":"Am J Med"},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/rheumatology\/41.9.1047","volume":"41","author":"AL Dolan","year":"2002","unstructured":"Dolan AL, Moniz C, Abraha H, Pitt P: Does active treatment of rheumatoid arthritis limit disease-associated bone loss?. Rheumatology (Oxford). 2002, 41: 1047-1051. 10.1093\/rheumatology\/41.9.1047.","journal-title":"Rheumatology (Oxford)"},{"key":"2388_CR6","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/art.11292","volume":"48","author":"M Vis","year":"2003","unstructured":"Vis M, Wolbink GJ, Lodder MC, Kostense PJ, Stadt van de RJ, de Koning MH, Dijkmans BA, Lems WF: Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum. 2003, 48: 2996-2997. 10.1002\/art.11292.","journal-title":"Arthritis Rheum"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJM199507203330302","volume":"333","author":"JR Kirwan","year":"1995","unstructured":"Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995, 333: 142-146. 10.1056\/NEJM199507203330302.","journal-title":"N Engl J Med"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"AA van Everdingen","year":"2002","unstructured":"van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002, 136: 1-12.","journal-title":"Ann Intern Med"},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1002\/art.21298","volume":"52","author":"B Svensson","year":"2005","unstructured":"Svensson B, Boonen A, Albertsson K, Heijde van der D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005, 52: 3360-3370. 10.1002\/art.21298.","journal-title":"Arthritis Rheum"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.48.7.535","volume":"48","author":"PN Sambrook","year":"1989","unstructured":"Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG: Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis. 1989, 48: 535-538. 10.1136\/ard.48.7.535.","journal-title":"Ann Rheum Dis"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","volume":"119","author":"RF Laan","year":"1993","unstructured":"Laan RF, van Riel PL, Putte van de LB, van Erning LJ, van't Hof MA, Lemmens JA: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993, 119: 963-968.","journal-title":"Ann Intern Med"},{"key":"2388_CR12","first-page":"1495","volume":"24","author":"AC Verhoeven","year":"1997","unstructured":"Verhoeven AC, Boers M: Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol. 1997, 24: 1495-1503.","journal-title":"J Rheumatol"},{"key":"2388_CR13","first-page":"S186","volume":"21","author":"V Strand","year":"2003","unstructured":"Strand V, Simon LS: Low dose glucocorticoids in early rheumatoid arthritis. Clin Exp Rheumatol. 2003, 21: S186-190.","journal-title":"Clin Exp Rheumatol"},{"key":"2388_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"17","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A: Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006, 17: 144-149. 10.1016\/j.tem.2006.03.009.","journal-title":"Trends Endocrinol Metab"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/03009740701394021","volume":"36","author":"B Tengstrand","year":"2007","unstructured":"Tengstrand B, Larsson E, Klareskog L, Hafstrom I: Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol. 2007, 36: 351-358. 10.1080\/03009740701394021.","journal-title":"Scand J Rheumatol"},{"issue":"Suppl 6","key":"2388_CR16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1007\/s001980070002","volume":"11","author":"PD Delmas","year":"2000","unstructured":"Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000, 11 (Suppl 6): S2-17. 10.1007\/s001980070002.","journal-title":"Osteoporos Int"},{"key":"2388_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s007740170002","volume":"19","author":"Y Nishizawa","year":"2001","unstructured":"Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M: Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone Miner Metab. 2001, 19: 338-344. 10.1007\/s007740170002.","journal-title":"J Bone Miner Metab"},{"key":"2388_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","volume":"18","author":"P Garnero","year":"2003","unstructured":"Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM: The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003, 18: 859-867. 10.1359\/jbmr.2003.18.5.859.","journal-title":"J Bone Miner Res"},{"key":"2388_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/ard.2007.076604","volume":"67","author":"F Chopin","year":"2008","unstructured":"Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T: Long term effects of Infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008, 67: 353-357. 10.1136\/ard.2007.076604.","journal-title":"Ann Rheum Dis"},{"key":"2388_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/jcb.240550309","volume":"55","author":"AM Delany","year":"1994","unstructured":"Delany AM, Pash JM, Canalis E: Cellular and clinical perspectives on skeletal insulin-like growth factor I. J Cell Biochem. 1994, 55: 328-333. 10.1002\/jcb.240550309.","journal-title":"J Cell Biochem"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/rheumatology\/keh421","volume":"44","author":"E Toussirot","year":"2005","unstructured":"Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cedoz JP, Wendling D: Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis. Rheumatology (Oxford). 2005, 44: 120-125. 10.1093\/rheumatology\/keh421.","journal-title":"Rheumatology (Oxford)"},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/rheumatology\/39.9.1031","volume":"39","author":"B Svensson","year":"2000","unstructured":"Svensson B, Schaufelberger C, Teleman A, Theander J: Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. Rheumatology (Oxford). 2000, 39: 1031-1036. 10.1093\/rheumatology\/39.9.1031.","journal-title":"Rheumatology (Oxford)"},{"key":"2388_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/03009748809098795","volume":"17","author":"C Ekdahl","year":"1988","unstructured":"Ekdahl C, Eberhardt K, Andersson SI, Svensson B: Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988, 17: 263-271. 10.3109\/03009748809098795.","journal-title":"Scand J Rheumatol"},{"key":"2388_CR25","volume-title":"South Med J","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S: Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. South Med J. 2008, online."},{"key":"2388_CR26","volume-title":"Operator manual, Expert-XL software version 1.7. Lunar Corporation","author":"Lunar","year":"1998","unstructured":"Lunar: Operator manual, Expert-XL software version 1.7. Lunar Corporation. 1998, Lunar Corporation Madison, USA"},{"key":"2388_CR27","first-page":"620","volume":"124","author":"P Bang","year":"1991","unstructured":"Bang P, Eriksson U, Sara V, Wivall IL, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh). 1991, 124: 620-629.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2388_CR28","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1210\/jc.80.9.2646","volume":"80","author":"A Hilding","year":"1995","unstructured":"Hilding A, Brismar K, Degerblad M, Thoren M, Hall K: Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab. 1995, 80: 2646-2652. 10.1210\/jc.80.9.2646.","journal-title":"J Clin Endocrinol Metab"},{"key":"2388_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/art.1780280403","volume":"28","author":"OS Als","year":"1985","unstructured":"Als OS, Gotfredsen A, Christiansen C: The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum. 1985, 28: 369-375. 10.1002\/art.1780280403.","journal-title":"Arthritis Rheum"},{"key":"2388_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/rheumatology\/30.2.86","volume":"30","author":"RC Butler","year":"1991","unstructured":"Butler RC, Davie MW, Worsfold M, Sharp CA: Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy. Br J Rheumatol. 1991, 30: 86-90. 10.1093\/rheumatology\/30.2.86.","journal-title":"Br J Rheumatol"},{"key":"2388_CR31","first-page":"1635","volume-title":"Kelley's Textbook of Rheumatology","author":"MLM Delaney","year":"2001","unstructured":"Delaney MLM: Metabolic Bone Disease. Kelley's Textbook of Rheumatology. Edited by: Ruddy S, Harris E, Sledge C. 2001, USA: WB Saunders Company, 2: 1635-1652. 6","edition":"6"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002, 13: 777-787. 10.1007\/s001980200108.","journal-title":"Osteoporos Int"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/00002281-200307000-00013","volume":"15","author":"E Canalis","year":"2003","unstructured":"Canalis E: Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2003, 15: 454-457. 10.1097\/00002281-200307000-00013.","journal-title":"Curr Opin Rheumatol"},{"key":"2388_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/096120339900800513","volume":"8","author":"S Khosla","year":"1999","unstructured":"Khosla S, Melton LJ, Riggs BL: Osteoporosis: gender differences and similarities. Lupus. 1999, 8: 393-396. 10.1177\/096120339900800513.","journal-title":"Lupus"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/ard.53.1.14","volume":"53","author":"AK Gough","year":"1994","unstructured":"Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P: Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis. 1994, 53: 14-17. 10.1136\/ard.53.1.14.","journal-title":"Ann Rheum Dis"},{"key":"2388_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/ard.55.5.288","volume":"55","author":"WF Lems","year":"1996","unstructured":"Lems WF, Gerrits MI, Jacobs JW, van Vugt RM, van Rijn HJ, Bijlsma JW: Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 1996, 55: 288-293. 10.1136\/ard.55.5.288.","journal-title":"Ann Rheum Dis"},{"key":"2388_CR37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1515\/CCLM.2003.160","volume":"41","author":"ML Sassi","year":"2003","unstructured":"Sassi ML, Aman S, Hakala M, Luukkainen R, Risteli J: Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis. Clin Chem Lab Med. 2003, 41: 1038-1044. 10.1515\/CCLM.2003.160.","journal-title":"Clin Chem Lab Med"},{"key":"2388_CR38","first-page":"1593","volume":"21","author":"A Kotaniemi","year":"1994","unstructured":"Kotaniemi A, Isomaki H, Hakala M, Risteli L, Risteli J: Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol. 1994, 21: 1593-1596.","journal-title":"J Rheumatol"},{"key":"2388_CR39","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/rheumatology\/33.11.1012","volume":"33","author":"L Paimela","year":"1994","unstructured":"Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J: Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol. 1994, 33: 1012-1016. 10.1093\/rheumatology\/33.11.1012.","journal-title":"Br J Rheumatol"},{"key":"2388_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/rheumatology\/37.1.27","volume":"37","author":"WF Lems","year":"1998","unstructured":"Lems WF, Van Veen GJ, Gerrits MI, Jacobs JW, Houben HH, Van Rijn HJ, Bijlsma JW: Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumatol. 1998, 37: 27-33. 10.1093\/rheumatology\/37.1.27.","journal-title":"Br J Rheumatol"},{"key":"2388_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","volume":"41","author":"AI Catrina","year":"2002","unstructured":"Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK: Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford). 2002, 41: 484-489. 10.1093\/rheumatology\/41.5.484.","journal-title":"Rheumatology (Oxford)"},{"key":"2388_CR42","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1007\/s00198-005-1973-6","volume":"16","author":"SK Jassal","year":"2005","unstructured":"Jassal SK, von Muhlen D, Barrett-Connor E, Rosen CJ: Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: the Rancho Bernardo Study. Osteoporos Int. 2005, 16: 1948-1954. 10.1007\/s00198-005-1973-6.","journal-title":"Osteoporos Int"},{"key":"2388_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1043-6618(03)00182-8","volume":"48","author":"F Dong","year":"2003","unstructured":"Dong F, Ren J: Insulin-like growth factors (IGFs) and IGF-binding proteins in nephrotic syndrome children on glucocorticoid. Pharmacol Res. 2003, 48: 319-323. 10.1016\/S1043-6618(03)00182-8.","journal-title":"Pharmacol Res"},{"key":"2388_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1530\/eje.0.1440237","volume":"144","author":"X Zhou","year":"2001","unstructured":"Zhou X, Loke KY, Pillai CC, How HK, Yap HK, Lee KO: IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH. Eur J Endocrinol. 2001, 144: 237-243. 10.1530\/eje.0.1440237.","journal-title":"Eur J Endocrinol"},{"key":"2388_CR45","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/BF03349028","volume":"19","author":"MF Prummel","year":"1996","unstructured":"Prummel MF, Wiersinga WM, Oosting H, Endert E: The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1. J Endocrinol Invest. 1996, 19: 620-623.","journal-title":"J Endocrinol Invest"},{"key":"2388_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1136\/ard.2005.040816","volume":"65","author":"P Sarzi-Puttini","year":"2006","unstructured":"Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M, Straub RH: Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006, 65: 301-305. 10.1136\/ard.2005.040816.","journal-title":"Ann Rheum Dis"},{"key":"2388_CR47","first-page":"397","volume":"128","author":"P Bang","year":"1993","unstructured":"Bang P, Degerblad M, Thoren M, Schwander J, Blum W, Hall K: Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome. Acta Endocrinol (Copenh). 1993, 128: 397-404.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2388_CR48","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jbmr.5650070912","volume":"7","author":"E Canalis","year":"1992","unstructured":"Canalis E, Avioli L: Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells. J Bone Miner Res. 1992, 7: 1085-1092.","journal-title":"J Bone Miner Res"},{"key":"2388_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cellimm.2007.09.010","volume":"252","author":"JC O'Connor","year":"2008","unstructured":"O'Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW: Regulation of IGF-I function by proinflammatory cytokines: At the interface of immunology and endocrinology. Cell Immunol. 2008, 252: 91-110. 10.1016\/j.cellimm.2007.09.010.","journal-title":"Cell Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar2542\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:30:31Z","timestamp":1728383431000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar2542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,5]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,12]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1186\/ar2542","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,5]]},"assertion":[{"value":"15 May 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R128"}}